|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cytomx Therapeutics, Inc. (CTMX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,160,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
47,819 |
75,591 |
103,916 |
162,805 |
| Total Sell Value |
$99,726 |
$138,068 |
$174,902 |
$267,502 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
10 |
14 |
26 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccarthy Sean A. |
CEO |
• • – |
2024-03-26 |
4 |
OE |
$1.57 |
$172,874 |
D/D |
109,768 |
634,249 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• • – |
2024-03-19 |
4 |
S |
$2.09 |
$10,986 |
D/D |
(5,268) |
117,728 |
|
- |
|
| Ogden Christopher |
SVP, Finance and Accounting |
• • – |
2024-03-19 |
4 |
S |
$2.09 |
$6,196 |
D/D |
(2,971) |
85,686 |
|
- |
|
| Mccarthy Sean A. |
CEO |
• • – |
2024-03-19 |
4 |
S |
$2.09 |
$42,175 |
D/D |
(20,223) |
524,481 |
|
- |
|
| Belvin Marcia |
SVP, Chief Scientific Officer |
• • – |
2024-03-19 |
4 |
S |
$2.09 |
$26,684 |
D/D |
(12,795) |
168,579 |
|
- |
|
| Landau Jeffrey B |
Chief Business Officer |
• • – |
2024-03-19 |
4 |
S |
$2.09 |
$13,685 |
D/D |
(6,562) |
110,060 |
|
- |
|
| Landau Jeffrey B |
Chief Business Officer |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
116,622 |
|
- |
|
| Chu Yu-Waye |
Chief Medical Officer |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
26,250 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
122,996 |
|
- |
|
| Mccarthy Sean A. |
CEO |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
544,704 |
|
- |
|
| Belvin Marcia |
SVP, Chief Scientific Officer |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
181,374 |
|
- |
|
| Ogden Christopher |
SVP, Finance and Accounting |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
88,657 |
|
- |
|
| Mccarthy Sean A. |
CEO |
• • – |
2023-12-20 |
4 |
S |
$1.38 |
$18,710 |
D/D |
(13,551) |
454,704 |
|
- |
|
| Ogden Christopher |
SVP, Finance and Accounting |
• • – |
2023-12-20 |
4 |
S |
$1.38 |
$2,747 |
D/D |
(1,990) |
48,657 |
|
- |
|
| Belvin Marcia |
SVP, Chief Scientific Officer |
• • – |
2023-12-20 |
4 |
S |
$1.38 |
$5,628 |
D/D |
(4,077) |
155,124 |
|
- |
|
| Landau Jeffrey B |
Chief Business Officer |
• • – |
2023-12-20 |
4 |
S |
$1.38 |
$5,628 |
D/D |
(4,077) |
86,622 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• • – |
2023-12-20 |
4 |
S |
$1.38 |
$5,629 |
D/D |
(4,077) |
97,996 |
|
- |
|
| Mccarthy Sean A. |
CEO |
• • – |
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
468,255 |
|
- |
|
| Belvin Marcia |
SVP, Chief Scientific Officer |
• • – |
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
159,201 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• • – |
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
102,073 |
|
- |
|
| Landau Jeffrey B |
Chief Business Officer |
• • – |
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
90,699 |
|
- |
|
| Ogden Christopher |
SVP, Finance and Accounting |
• • – |
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
50,647 |
|
- |
|
| Mccarthy Sean A. |
CEO |
• • – |
2023-09-22 |
4 |
S |
$1.30 |
$18,987 |
D/D |
(14,601) |
430,755 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• • – |
2023-09-22 |
4 |
S |
$1.30 |
$7,135 |
D/D |
(5,486) |
80,609 |
|
- |
|
| Landau Jeffrey B |
Chief Business Officer |
• • – |
2023-09-22 |
4 |
S |
$1.30 |
$5,356 |
D/D |
(4,119) |
76,379 |
|
- |
|
286 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
